SCHEMBL615592

SCHEMBL615592

FC(F)(F)Oc1ccccc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.38
GAA P10253 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
KCNK3 O14649 3/20 0.37
KCNK9 Q9NPC2 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
SCN9A Q15858 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD11B1 P28845 1/20 0.37
EPHX2 P34913 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA5A P35218 1/20 0.35
CA9 Q16790 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29471353 1.00 HTR7 (0.38) HTR7GAARXRARXRBRXRG
SCHEMBL9804688 0.82 HTR7 (0.36) HTR7L3MBTL1ALDH1A1CA1CA2
SCHEMBL3399136 0.82 HTR7 (0.36) HTR7L3MBTL1ALDH1A1CA1CA2
SCHEMBL4654446 0.82 RXRA (0.47) GAARXRARXRBRXRGKCNK3
SCHEMBL16184453 0.80 MPL (0.44) GAARXRARXRBRXRGKCNK3
SCHEMBL1619385 0.80 MEN1 (0.36) HTR7GAAL3MBTL1ALDH1A1CA1
SCHEMBL25310703 0.79 KDM4E (0.34) GAARXRARXRBRXRGKCNK3
SCHEMBL10874519 0.79 MRGPRX4 (0.38) L3MBTL1SCN9AALDH1A1
SCHEMBL5733587 0.79 HSD11B1 (0.36) KCNK3KCNK9L3MBTL1SCN9AALDH1A1
SCHEMBL4657366 0.79 MPL (0.40) GAARXRARXRBRXRGKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112159329-B Co-production preparation method of o-amino trifluoromethoxybenzene and m-amino trifluoromethoxybenzene 大连奇凯医药科技有限公司 2022-09-06 CN claimed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 EP disclosed
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20250154193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Cholesgen (Shanghai) Co., Ltd. (CN) 2025-05-15 US disclosed
EP-3870577-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2025-03-19 EP disclosed
WO-2025043225-A2 DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 GENENTECH, INC. (US) 2025-02-27 WO disclosed
WO-2025021193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 珂阑(上海)医药科技有限公司 2025-01-30 WO disclosed
WO-2025020191-A1 STEROID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 珂阑(上海)医药科技有限公司 2025-01-30 WO disclosed
EP-0130876-B1 PROCESS FOR THE SIMULTANEOUS HALOGENATION AND FLUORINATION OF AROMATIC COMPOUNDS RHONE-POULENC CHIMIE (FR) 1988-04-20 EP disclosed
EP-0244328-A2 Process for the preparation of aromatic aldehydes RHONE-POULENC CHIMIE (FR) 1987-11-04 EP disclosed
EP-0244329-A2 Process for the preparation of aromatic aldehydes RHONE-POULENC CHIMIE (FR) 1987-11-04 EP disclosed
US-4575571-A HALOGEN IN LIQUID HYDROGEN FLUORIDE RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1986-03-11 US disclosed
US-4316994-A Preparation of 4-fluoro-3-phenoxy-toluene BAYER AKTIENGESELLSCHAFT (DE) 1982-02-23 US disclosed
US-4311710-A Anticoccidial formulation and method ELI LILLY AND COMPANY (US) 1982-01-19 US disclosed
US-4266082-A Preparation of 4-fluoro-3-phenoxy-toluene BAYER AKTIENGESELLSCHAFT (DE) 1981-05-05 US disclosed
US-4259532-A TRIFLUOROMETHOXYHALOPHENOL E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-03-31 US disclosed
US-4192669-A DERIVATIVES OF 2-(4-(4-(TRIFLUOROMETHOXY)-PHENOXY)PHENOXY)AALKANOIC ACIDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-03-11 US disclosed
US-4031119-A LUBRICANTS, GREASES, SEALS PONOMAREV ALEXEI IVANOVICH 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A HTR7 3265/4885GAA 3260/4885RXRA 400/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 HTR7 4013/4885GAA 4/4885RXRA 4071/4885
US-20250154193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SREBF1, SREBF2, CYP46A1 HTR7 4039/4885GAA 1779/4885RXRA 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.